Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of EVOK opened at $3.17 on Thursday. The company has a 50-day moving average of $2.77 and a 200 day moving average of $4.03. Evoke Pharma has a 1-year low of $1.94 and a 1-year high of $12.32. The firm has a market capitalization of $4.73 million, a price-to-earnings ratio of -0.29 and a beta of 0.16.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Monday, May 12th. The specialty pharmaceutical company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The business had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.32 million.

Institutional Trading of Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC lifted its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.